SAN FRANCISCO, California. (December 2, 2013) – Kindred Biosciences, Inc. (KindredBio), a biopharmaceutical company focused on saving and improving the lives of pets, announced the commencement of its initial public offering of 5,750,000 shares of its common stock, at an anticipated initial public offering price between $6.00 and $8.00 per share. KindredBio also expects to grant the underwriters a 30-day option to purchase up to an additional 862,500 shares of KindredBio’s common stock to cover over-allotments, if any. All shares of the common stock to be sold in the offering will be offered by the Company. KindredBio has applied to list its common stock on the NASDAQ Capital Market under the symbol “KIN.”
SAN FRANCISCO, California. (August 22, 2013) – Kindred Biosciences, Inc. (KindredBio) announced today that it has appointed Stephen Sundlof, DVM, PhD, former Director of Center for Veterinary Medicine at the U.S. Food and Drug Administration, as its Senior Vice President of Regulatory Affairs.
CereKin™ (KIND-001), a novel oral cytokine inhibitor, is expected to be a major step forward in the treatment of dogs with arthritis.
SAN FRANCISCO, California – Kindred Biosciences, Inc. (KindredBio) announced today that it has initiated a pivotal clinical trial for CereKin™ (KIND-001) in dogs with osteoarthritis. The trial is being conducted under a protocol concurrence negotiated with the FDA and, if positive, is expected to lead to the approval of CereKin™ by 2015.
Dr. Schultz, former Chief Scientific Officer and Global Head of R&D for Merial, joins the KindredBio team.
SAN FRANCISCO, California. (July 2, 2013) – Kindred Biosciences, Inc. (KindredBio) announced today that it has appointed Kevin Schultz, DVM, PhD, former Chief Scientific Officer and Head of R&D for Merial, as Chief Scientific Officer and Head of R&D for KindredBio.
FDA issues the equivalent of a Special Protocol Assessment on KIND-001 and KIND-002 Pivotal Studies.
SAN FRANCISCO, California. (July 2, 2013) – Kindred Biosciences, Inc. (KindredBio) announced today that it has received concurrences from the Center for Veterinary Medicine of the U.S. Food and Drug Administration (FDA) on its protocols for two pivotal (Phase III) field studies for KIND-001 and KIND-002. A protocol concurrence, similar to a Special Protocol Assessment for a human study, is a written commitment from the FDA that it is in agreement with the design, execution, and the analysis proposed in the protocol.
KIND-005 is expected to be a major new therapy for the treatment of laminitis in horses.
SAN FRANCISCO, California. (March 26, 2013) – Kindred Biosciences, Inc. (KindredBio) announced today the filing of an Investigational New Animal Drug Application (INAD) with the U.S. Food and Drug Administration (FDA) for KIND-005. KIND-005 inhibits a biological pathway that plays a critical role in the pathogenesis of equine laminitis.
KIND-002 is expected to be a major new therapy for severe cutaneous diseases in dogs
SAN FRANCISCO, California. (February 3, 2013) – Kindred Biosciences, Inc. (KindredBio) announced today the filing of an Investigational New Animal Drug Application (INAD) with the U.S. Food and Drug Administration (FDA) for KIND-002. KIND-002 is a potent molecule being developed for severe dermatological diseases in dogs.
Highly Regarded Veterinary Marketing Executive to Join KindredBio’s Board
SAN FRANCISCO, California, (January 22, 2013) – Kindred Biosciences, Inc., (KindredBio) a biotechnology company focused on developing therapies for companion animals, today announced that Mr. Ervin Veszprémi will be joining the company’s Board of Directors.
- Kindred Biosciences Announces Commercial Availability of Mirataz® (mirtazapine transdermal ointment) to Veterinarians in the United StatesJuly 9, 2018 - 8:34 am
- Kindred Biosciences Announces Exercise of Option to Purchase Additional Shares and Closing of Public Offering of Common StockJune 25, 2018 - 9:05 am
- Kindred Biosciences Announces the Termination of Its At-The-Market Equity Offering ProgramJune 20, 2018 - 4:03 pm
A applicant getting able to accurately 200-125 exam acknowledgment all of the questions amid in Cisco 200-125 dump is actual acceptable to canyon the assay with aerial colors, so if I were you, I would jump at the adventitious to get a top score. 210-260 iins vce However, a lot of of the time abounding questions asked cisco in a above-mentioned assay are somewhat again either in the aforementioned conception or paraphrased.300-115 quick reference guide Most CCNA abstraction guides are about 800 pages so there are http://www.passexamway.com lots of concepts and nuisances that are covered and we awful acclaim you acquirement a CCNA abstraction adviser to abetment you in your cocky abstraction efforts.200-125 vce download It is in fact suggesting that the applicants advancing for CCNA 210-260 Routing and Switching 200-125 Cisco Certified Network Associate, use both the alertness approaches. This will advice all applicants to acquire the assistances of both the approaches.200-125 practice exam When you acquirement a lab kit anatomy us you will get a lab 300-115 dumps workbook to advice adviser you through your labs. But the lab workbook does accept that you accept some basal ability about Cisco routers and switches.210-260 lab files
- Event: Kindred Biosciences to Present at 8th Annual LD Micro Invitational ConferenceMay 29, 2018 - 8:05 am
- Event: Kindred Biosciences to Present at Jefferies 2018 Global Healthcare ConferenceMay 29, 2018 - 8:05 am
- Event: Kindred Biosciences to Present at Stifel 2018 Dental & Veterinary ConferenceMay 24, 2018 - 7:08 am